Introduction
============

Rapid onset, short duration, easy titration, and remarkable safety profile makes propofol one of the most popular intravenous anesthetic drugs used today. However, its analgesic effects are poor. In addition, pain on injection tend to be so severe that up to 80% of patients recall the incident \[[@B1]\]. This pain is known to be resulting from direct irritation of peripheral nerve endings on the intima of blood vessels \[[@B2]\] and the activation of the plasma kinin cascade with release of bradykinin which induces venodilation and hyperpermeability, thus increasing contact with aqueous propofol and free nerve endings \[[@B3]\].

Among numerous reports in efforts to decrease propofol injection pain, the most effective combination of drug and non-drug intervention based on a quantitative systematic review has been revealed to be pretreatment with lidocaine in combination with a tourniquet for venous occlusion \[[@B4]\]. Non-drug interventions include the use of the antecubital vein, central venous catheter, cooling or heating propofol, local cooling, and changing concentrations of free propofol by modifications of injected solutions \[[@B3][@B5][@B6][@B7][@B8]\]. Drug interventions include combination of nicardipine and lidocaine, iontophoretically applying lidocaine, dexmedetomidine, ketamine, and dexamethasone \[[@B1][@B9][@B10][@B11][@B12]\]. Nicorandil, a vasodilatory drug for treating angina, can reduce propofol injection pain from 77% in the control group to 30% in the study group \[[@B13]\]. The use of the antecubital vein instead of the dorsal vein of the hand for injection has been found to be the most effective non-drug intervention due to its larger diameter and faster flow rate while minimizing contact of propofol with the endothelial wall with more blood available acting as a buffer \[[@B14]\]. Slowing the rate of injection has been reported to cause more discomfort \[[@B3]\].

Unfortunately, the majority of these reports conclude that a single method is insufficient in eliminating propofol injection pain. Studies investigating the effects of propofol at various temperatures have been carried out. However, no previous study has demonstrated the contribution of hyperthermia associated venodilation in reducing propofol injection pain. Interestingly, thermal stimulus below 43℃ with a low risk of causing burn \[[@B15]\] is known to be an effective venodilating technique among nurses \[[@B16]\] to increases both cutaneous blood flow and venodilation \[[@B17]\] for peripheral intravenous cannulation. This non-pharmalogical intervention has the advantage of being safe and noninvasive. In addition, it has minimal risks of burn injury compared to direct skin warming or forced air warming. Based on previous findings, we carried out a prospective, randomized, and controlled trial to test the hypothesis that warming the dorsal vein prepared for injection with intravenous carrier fluids heated to approximately 40℃ would increase blood flow and venodilation while minimizing contact of propofol with the endothelial wall, thus decreasing injection pain. Another objective was to determine if heated carrier fluids would enhance the effect of lidocaine injected prior to propofol to decrease injection pain.

Pilot study
-----------

Prior to this study, we performed a pilot study in 80 patients with four different types of known and unknown methods to alleviate propofol pain. We also tested temperature change of the heated carrier fluids and room temperature fluids after 20 minutes, tympanic temperatures, and skin temperatures to make sure that patients were not subjected to burn injury. Temperature of carrier fluids were measured with a digital temperature probe (Brannan Digital Thermometer, Cleator Moor, England). Tympanic temperatures were measured with a tympanic thermometer (Braun Thermoscan Ear Thermometer, Kronberg, Germany). Skin temperatures were measured with a skin temperature probe (DATAQ instruments, DI-1000tc series revision A, Akron, OH, USA).

All patients were questioned on verbal pain score (VPS) after injection of 25% of 2 mg/kg propofol. Group T (n = 30) tested the efficacy of the tourniquet method (pretreatment with 0.5 mg/kg 1%lidocaine in combination with a tourniquet for venous occlusion), in which 26 patients perceived no pain (VPS grade 0). Group H (n = 10) received 200 ml of warm carrier fluids heated to 40℃ for approximately 20 minutes, in which 6 patients perceived no pain. Group L (n = 30) was given 0.5 mg/kg 1%lidocaine 30 seconds prior to propofol, in which 14 patients were pain free. We instituted a fourth method, Group HL (n = 10), in which heated 0.5 mg/kg 1%lidocaine (41℃) was given prior to propofol, in which all patients complained of severe pain, and so this method was not further pursued.

Initial temperature of each carrier fluid was measured with a digital temperature probe, which did not surpass 41℃ or fall below 40℃ after 20 minutes. The initial temperature of room temperature fluids was approximately 23--24℃ before and after 20 minutes. There were also no tympanic or skin temperature changes after the administration of 200 ml of heated carrier fluids. Therefore, we did not further pursue the measurement of skin temperatures in the main study. However, we included tympanic membrane temperatures in the demographic data.

Materials and Methods
=====================

Materials
---------

After obtaining approval from the ethics committee of Chungnam National University Hospital and receiving informed consent from patients, 90 patients aged 18 to 65 classified as American Society of Anesthesiologists physical status I or II scheduled to undergo either elective or urgent surgery under general anesthesia were enrolled in this study ([Fig. 1](#F1){ref-type="fig"}). Institutional Review Board approval was obtained before the study was conducted. Exclusion criteria included those who were pregnant and breastfeeding, pediatrics, patients with cardiovascular, renal, hepatic diseases, patients with neurological deficits, patients with psychiatric diseases, patients with difficulty in communication, patients with known anaphylaxis or allergies to local anesthetics, patients with skin damage or erythema, edema, or with concomitant use of topically applied analgesics on the study limb were excluded as well. Patients who were on low-dose aspirin and/or clopidogrel were also excluded.

Method
------

Patients were randomly allocated into three groups. Group W was given 200 ml of heated carrier fluids (40℃) prior to 25% of 2 mg/kg 1%propofol injection. Group L was given 200 ml of warm carrier fluids prior to 0.5 mg/kg 1%lidocaine pretreatment and 25% of 2 mg/kg 1%propofol injection. Group C was given 200 ml of room temperature fluids prior to 25% of 2 mg/kg 1%propofol injection (control group). Temperature of the heated carrier fluid was measured each time before its use to make sure it was within acceptable limits (40.0--40.9℃). We limited the amount of fluids to 200 ml to exclude vasodilation from preload effects of functional intravascular volume \[[@B18]\]. All measurements were performed at room temperature of the operating room (23--24℃) with humidity of 35--40%.

All patients were premedicated with 0.2 mg glycopyrrolate before anesthetic induction. Electrocardiogram, heart rate (HR), pulse oximetry (SpO~2~), and noninvasive mean blood pressure (MBP), were measured before anesthetic induction. An 18 G needle was inserted the night before surgery to prevent dehydration. The site of IV access was limited to either the right or left dorsum of the hand. Before anesthetic induction, all three groups received 200 ml of carrier fluids for 20 minutes. Only Group L received a bolus of 0.5 mg/kg 1%lidocaine 1 minute before propofol injection. At induction, 25% of 2 mg/kg 1%propofol, a dose known to induce injection pain without losing consciousness, was administered to patients before asking their VPS on a 0--3 grade (0 = none, negative response to questioning; 1 = mild pain, pain responding to questioning only, without any behavioral signs; 2 = moderate pain, pain responding to questioning and accompanied by a behavioral sign, or pain reported simultaneously with a behavioral sign, or pain reported simultaneously with a behavioral sign, but without questioning; 3 = severe pain, strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears). After questioning, the remainder of propofol (75% of 2 mg/kg) was administered to complete anesthetic induction and rocuronium 0.6 mg/kg was administered for neuromuscular blockade after loss of eyelash reflex. Anesthesia was maintained with 1 MAC desflurane and 50% oxygen with air. Remifentanil was continuously infused after measuring vital signs and propofol injection to optimize intubation conditions. Changes in vital signs were measured before anesthetic induction (MBP 1, HR 1, SpO~2~ 1), after injection of propofol 2 mg/kg (MBP 2, HR 2, SpO~2~ 2), and immediately after intubation (MBP 3, HR 3, SpO~2~ 3). Body temperatures initially (BT 1) and after intubation (BT 2) were also recorded.

Data analyses
-------------

Statistical analyses were conducted using IBM SPSS statistics software (version 20.0, IBM Corp., Armonk, NY, USA) and data expressed as mean ± SE. The incidence of pain residing from placebos was estimated to be 80%, and a 50% reduction in the group injected with the study fluid was considered to be of clinical importance. Based on an α error of 0.05 and a β error of 0.2 (power = 0.8), a minimum sample size was determined to be 23 patients per group (22.305 patients from the equation by Fleiss). With additional patients for attrition, 30 patients were chosen to distinguish any variance. Demographic data were compared using ANOVA and sex was compared using Pearson χ^2^ test. The incidence and severity of propofol injection pain between the groups were compared using both χ^2^ test and Fisher\'s exact test. Comparisons among the three groups were performed using Mann-Whitney test or one way ANOVA. Vital signs (MBP, HR, SpO~2~, and BT) were compared using ANOVA. A P value of less than 0.05 was considered to be statistically significant.

Results
=======

A total of 90 patients completed the study. Demographic characteristics (sex, age, height, weight) are shown in [Table 1](#T1){ref-type="table"}. The incidence and severity of propofol injection pain are summarized in [Table 2](#T2){ref-type="table"}. Vital trends (MBP, HR, SpO~2~, BT) are shown in [Table 3](#T3){ref-type="table"}.

The incidence of propofol injection pain was statistically different between groups. A total of 14 patients in Group W (46.7%), 11 in Group L (36.7%), and 4 (13.3%) in Group C were completely free of injection pain (P = 0.002, Pearson χ^2^ test). The severity of propofol injection pain was also statistically different (χ^2^ test, P = 0.002) among the three groups. Six patients in Group C experienced severe pain (VPS 3) while 0 patients in Group W and 1 patient in Group L experienced severe pain. Using Fisher\'s exact test, Group W and Group C showed statistically significant difference (P = 0.018) in the incidence of propofol injection pain, while Group L and Group C also showed statistically significant difference (P = 0.036) in the incidence of propofol injection pain. There was no statistically significant difference between Group W and Group L (P = 0.3) in the incidence of propofol injection pain. Group W (P = 0.001) and Group L (P = 0.001) showed statistically significant reduction in the incidence of propofol injection pain when compared to Group C. However, Group W and Group L showed no statistically significant difference (P = 0.727, Mann-Whitney test). Pearson χ^2^ test also showed statistically significant difference in propofol injection pain between Group W (P = 0.005) or between Group L (P = 0.037) compared to group C, but no statistically significant difference (P = 0.432) between Group W and Group L.

There were no statistically significant differences regarding demographic data. However, MBP after the injection of propofol (MBP2) in Group C was higher compared to those in the other groups (P = 0.003).

Discussion
==========

This present study compared the effects of heated carrier fluids in decreasing propofol injection pain. Although the methods are slightly different, our results are fairly consistent with those of other studies in which local warming or forced air warming of the intravenous site reduced propofol injection pain \[[@B19]\]. The assumed mechanism is that thermal stimulus increases blood flow and allows for venodilation, thus diluting propofol, letting it flow mainstream of the vascular lumen and minimize contact with vascular epithelial cells. A study examining the response of skin microvasculature on transdermally applied acetylcholine or local heating to 41℃ to which patients are not at risk of potential burn injury has found that the former increased blood flow reaching a plateau while the latter induced dose-dependent vasodilation \[[@B20]\]. This implicates that vasodilation promoted by hyperthermia is more capable of inducing changes in hemodynamics, increasing blood flow rate, altering pharmacokinetics of drugs and therapeutic responses, accelerating drug injection, and increasing drug absorption \[[@B21]\]. Thus, propofol injection pain can be decreased by giving thermal stimulation with heated carrier fluids.

The use of heat application together with local anesthetics to produce a sensory block to alleviate pain has also been reported. Warmed lidocaine injected intra-articularly reduced intraoperative and postoperative analgesia requirements \[[@B22]\]. Placing a heating patch on top of a topical lidocaine 70 mg/tetracaine 70 mg patch to increase skin temperatures approximately 5℃ to facilitate delivery has been reported to provide significant pain relief \[[@B23]\]. However, propofol injection after pretreatment with heated 0.5 mg/kg 1%lidocaine in our pilot study was ineffective. Although we hypothesized that heated carrier fluids would synergize with the local anesthetic\'s properties, analgesic effects were lower than that of sole administration of heated carrier fluids. This may be due to heating of the pretreated 1%lidocaine when injected together with heated carrier fluids. Topical lidocaine and prilocaine was reported to eliminate the initial response of rapid vasodilation \[[@B24]\], which may have hindered the vasodilatory effects of heated carrier fluids.

In order to estimate the appropriate time for the infusion of heated carrier fluids to achieve maximum results, we searched for reports on skin perfusion in response to heat application. Minson et al. \[[@B25]\] found two mechanisms independent from each other that might have contributed to the increase in skin blood flow in a biphasic manner. The first is a fast responding axon mediated reflex that causes a vasodilatory "peak," while a slower response mediated production of nitric oxide creates a vasodilatory "plateau." The second response of nitric oxide to induce vasodilation occurs approximately 20 minutes after heat application. However, further prolongation may induce sweating and vasoconstriction, which is why we decided to use a 20 minute stimulus interval.

A statistically significant temporary increase in MBP was found after the injection of propofol in the control group (P = 0.003). This increase is likely due to patient movement or anxiety from pain during propofol injection. This finding is inconsistent with the report that women have lower pain thresholds and tolerance to nociceptive stimulation compared to men \[[@B26]\] and seems to be independent of the influence of sex.

Our study has several limitations. First, we were unable to control temperature decrease of heated carrier fluids during the first 20 minutes. We were only able to make sure that the initial temperature of carrier fluids were between 40.0--40.9℃ and that approximately 200 ml were infused in each patient prior to propofol injection. Fortunately, within the 20 minutes of our study, temperatures of the heated carrier fluids did not fall drastically (40.0--40.9℃). In addition, temperatures of the room temperature fluids did not change before infusion and after 20 minutes of injection. Second, we were unable to measure venous temperature changes or the degree of venous dilation before and after 20 minutes of injection. Temperature changes of the tympanic membrane and skin are limited in explaining the effects of heated carrier fluids because, for optimal biophysical effects extracted from heat therapy to occur, an increase of 3--4℃ in skin temperature is needed \[[@B27]\]. This was not the case in our study. Statistically significant increase in median vein diameters after thermal stimulus has been noted by by Tokizawa et al. \[[@B28]\], which were comparable with those of van Bemmelen et al. \[[@B29]\], due to increase in sympathetic vasodilation \[[@B30]\]. Therefore, median vein diameter after thermal stimulus should be included as an important parameter in future studies. Third, switching fluids and waiting for venodilation is cumbersome and may prolong induction time, which is problematic in busy hospitals. However, intravenous warming is simple and non-invasive, without risks of burn, without affecting systemic hemodynamics. Fourth, our results were statistically significant in reducing propofol injection pain but were not superior to previously studied interventions, such as the tourniquet method. Fifth, factors such as patient mood or physical condition might have influenced study results, and these limitations must be taken into account in future studies.

Propofol injection pain still remains a major problem because its complete elimination is challenging. Despite our limitations, our study demonstrated that using heated carrier fluids is a safe, non-invasive, non-pharmacological intervention in decreasing propofol injection pain. Therefore, if the dorsal vein is the site of injection, we recommend infusing heated carrier fluids before anesthetic induction to enhance analgesic effects and reduce propofol injection pain in adjunct with other effective techniques. For example, use of the tourniquet method (pretreatment with 0.5 mg/kg lidocaine in combination with a tourniquet for venous occlusion), which is most effective in reducing propofol injection pain with heated carrier fluids for synergistic effects may be of benefit. However, such methods also need to be further researched. Additionally, the use of warm intravenous fluids with pretreatment of lidocaine needs to be further investigated by performing actual measurements of venous diameters to identify any delay or reduction in initial venodilation.
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###### Demographic Data

![](kjae-70-33-i001)

                Group C       Group W       Group L       P value
  ------------- ------------- ------------- ------------- ---------
  Sex (M/F)     20/10         13/17         17/13         0.189
  Age (yr)      38.8 ± 2.8    45.2 ± 2.2    42.7 ± 2.5    0.195
  Height (cm)   166.1 ± 1.7   163.1 ± 1.4   164.3 ± 1.3   0.384
  Weight (kg)   67.5 ± 2.1    60.8 ± 1.7    63.5 ± 2.6    0.091

Data are expressed as mean ± SE or number of patients. There were no statistically significant differences among the groups. Group C: control group, Group W: 200 ml of warm carrier fluids, Group L: 200 ml of warm carrier fluids prior to 0.5 mg/kg 1%lidocaine pretreatment.

###### Incidence and Severity of Propofol Injection Pain
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          Group C   Group W   Group L   Total   
  ------- --------- --------- --------- ------- ----
  Grade   0         4         14        11      29
  1       8         9         14        31      
  2       12        7         4         23      
  3       6         0         1         7       
  n                 30        30        30      90

Data are expressed as number of patients. There was statistically significant difference between Group W and Group C and between Group L and Group C. However, there was no statistically significant difference between Group W and Group L. Group C: control group, Group W: 200 ml of warm carrier fluids, Group L: 200 ml of warm carrier fluids prior to 0.5 mg/kg 1%lidocaine pretreatment.

###### Vital Signs
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                         Group C (n = 30)   Group W (n = 30)   Group L (n = 30)   P value
  -------- ------------- ------------------ ------------------ ------------------ ---------
  MBP      1             91.8 ± 1.8         89.4 ± 2.6         85.9 ± 2.2         0.182
  2        89.1 ± 2.7    78.8 ± 2.1         80.1 ± 1.9         0.003              
  3        104.9 ± 4.3   98.6 ± 2.9         98.3 ± 2.9         0.305              
  HR       1             72.9 ± 2.6         73.3 ± 2.4         68.4 ± 2.5         0.318
  2        73.6 ± 2.5    76.4 ± 2.3         75.2 ± 1.9         0.675              
  3        88.8 ± 3.2    92.9 ± 2.5         84.9 ± 1.6         0.084              
  SpO~2~   1             99.1 ± 0.3         99.1 ± 0.2         98.9 ± 0.2         0.641
  2        99.9 ± 0.0    99.9 ± 0.1         99.6 ± 0.3         0.318              
  3        99.9 ± 0.0    100.0 ± 0.0        99.8 ± 0.2         0.483              
  BT       1             36.7 ± 0.0         36.8 ± 0.1         36.6 ± 0.1         0.457
  2        36.7 ± 0.0    36.7 ± 0.1         36.6 ± 0.1         0.235              

Data are expressed as mean ± SE. There was statistically significant difference in MBP measured after propofol injection among the three groups (MBP 2). There were no statistically significant difference among the three groups regarding other vital signs (MBP: mean blood pressure, HR: heart rate, SpO~2~: oxygen saturation, BT: body temperature). Group C: control group, Group W: 200 ml of warm carrier fluids, Group L: 200 ml of warm carrier fluids prior to 0.5 mg/kg 1%lidocaine pretreatment.
